How one mother's battle with eczema and steroid withdrawal led her to create Derma Warrior — and what patients need to know

Key Highlights
Introduction
The cycle that pushed her to act: steroid creams, relief and relapse
From private struggle to public solution: the birth of Derma Warrior
What zinc does and why a zinc balm can help oozy eczema
The psychological toll: isolation, stigma and "PTSD" reactions
Patient education and clinical gaps: what the story reveals
Understanding topical steroid withdrawal: evidence, controversies and practical realities
Balancing efficacy and safety: how to use topical steroids responsibly
Managing flare symptoms at home: practical tactics that complement medical care
When to seek medical attention — and what to ask for
The marketplace problem: unlabelled creams and consumer risk
Entrepreneurship under pressure: running a small health brand while parenting
Community response: how patient networks shape understanding and care
What clinicians can learn from patient innovators
Practical takeaways for people living with eczema or steroid withdrawal concerns
Real-world examples beyond Abeola: patient-led relief and the need for guidance
Moving forward: education, regulation and shared decision-making
Voices that matter: patients, clinicians and regulators in conversation
FAQ

Key Highlights

Prolonged topical steroid use can trigger cycles of flare-ups and withdrawal; personal experience drove Abeola Johnson to develop a zinc-based balm and start Derma Warrior in 2021.
Abeola’s approach focuses on drying oozing skin, rebuilding the skin barrier and reducing itch; her story spotlights gaps in patient education, the psychological toll of chronic skin disease, and the risks of unlabelled topical products.
Practical options for people living with eczema include measured steroid use under clinical guidance, barrier-repair emollients, zinc-based topical preparations, psychosocial support, and careful evaluation of over‑the‑counter remedies.

Introduction

Abeola Johnson spent years trapped in a cycle many people with eczema know too well: short-term relief from topical steroids followed by increasingly severe flare-ups when treatment stopped. The pattern left her skin thin, cracked and weeping and caused intense embarrassment and social withdrawal. The intervention that ended her isolation was not a new prescription from a clinic but a balm she developed herself — a zinc-based formula designed to dry oozing lesions, calm itching and support skin repair. That product became the seed of Derma Warrior, a small business Abeola launched in 2021 after friends and family began asking for what she had used.

Her story touches on several issues that go far beyond one person’s routine: how topical steroids are prescribed and understood, how withdrawal from chronic steroid use can manifest, the gaps in public and clinical education about safe long-term treatment, and the real-life pressures of creating health solutions while balancing parenting and running a business. This article traces Abeola’s experience, explains the science and practicalities behind zinc and barrier care, outlines what clinicians and patients disagree about when it comes to steroid withdrawal, and offers clear, evidence‑informed guidance for people navigating eczema treatment today.

The cycle that pushed her to act: steroid creams, relief and relapse

Eczema — clinically, atopic dermatitis — often follows a relapsing course. For many people, standard treatment is straightforward: emollients to restore moisture and topical corticosteroids (TCS) for flares. For Abeola, those flares became harder to break. She reports being prescribed steroid creams for years, and at one point using an over-the-counter product from a local shop that later turned out to contain steroids despite no indication on the ingredient list. Every time she stopped, symptoms returned worse than before.

Her description matches what patients call topical steroid withdrawal (TSW) or red skin syndrome: burning, intense itch, redness, flaking and oozing that can follow cessation of long-term or inappropriate steroid use. For Abeola the most affected areas were her hands — they split with movement and were so fragile that she sometimes couldn’t style her youngest daughter’s hair. The visible nature of the condition triggered deep stigma; she described running back into the house to avoid neighbours and feeling like people physically recoiled when they saw her skin.

Clinically, dermatologists recognise topical corticosteroids as effective anti-inflammatory agents when used appropriately. They also caution about potential adverse effects of long-term or unsupervised use: skin thinning (atrophy), striae, easy bruising, and, in some patients, a rebound phenomenon when steroids are stopped. The debate centres on how often true withdrawal occurs and under what circumstances. Many clinicians advise careful, time-limited steroid use with plans to step down and maintain with emollients, while patient groups report prolonged, distressing withdrawal experiences when steroids are used continuously, in high potency, or on sensitive skin sites.

Abeola’s experience illustrates two intersecting problems: the physical harm caused when skin is repeatedly subjected to potent anti-inflammatories without an effective long-term skin-restorative plan, and the public-health gap when topical steroids are present in unregulated or improperly labelled products. That latter factor — an unlabelled steroid cream purchased locally — meant she was using a medication without clinical oversight, likely contributing to dependency and worsening disease on withdrawal.

From private struggle to public solution: the birth of Derma Warrior

Starting Derma Warrior in 2021 was not a business plan: it was an organic response to a problem she had solved for herself. Friends and family who saw Abeola’s skin improve reached out for help, and she began to create and share what worked. Her core product is a zinc balm she formulated to dry oozing lesions, reduce itch and help rebuild damaged skin.

The motivation behind a patient-led product is instructive. Clinicians prescribe treatments, but daily management of chronic skin disease takes place at home. Patients adapt products, combine treatments, and look for topical solutions that reduce immediate symptoms — especially weeping and itch — which are among the most distressing and functionally limiting features of severe eczema. When mainstream options do not seem to provide durable relief, or when patients fear side effects, some turn to home-formulated or boutique products. For Abeola, that experimentation yielded a preparation that visibly helped and gave her back small freedoms: going outside without hiding, holding her children without pain, and re-engaging socially.

Derma Warrior emerged at the intersection of necessity, lived experience and entrepreneurship. Building a business taught Abeola lessons about product development, regulatory pathways, customer trust and the logistics of selling and scaling while parenting three children. Her persistent messages from customers — gratitude for symptom relief and improved quality of life — helped her continue despite the stresses of running a small company.

Her experience highlights a larger phenomenon: many health-product innovations arise from patients who translate their lived knowledge into tangible solutions. These patient-led innovations often address immediate needs neglected by the healthcare market, but they also face hurdles: ensuring safety, efficacy, accurate labelling, consistent production and navigating regulations that govern topical medical products.

What zinc does and why a zinc balm can help oozy eczema

Zinc has long been used in dermatology for its barrier and wound-care properties. Products containing zinc oxide or zinc salts appear in diaper-rash ointments, barrier creams and formulations aimed at drying exudate. The mechanisms relevant to eczema and oozing lesions include:

Barrier formation: Zinc oxide creates a physical barrier that protects the damaged skin from irritants and moisture loss, allowing the surface to rest and heal.
Drying action: The formulation can absorb and reduce weeping or oozing from excoriated lesions, which reduces maceration and secondary infection risk.
Mild antimicrobial and anti‑inflammatory properties: Zinc has modest antimicrobial activity and plays a role in wound healing and keratinocyte function, supporting restoration of the epidermis.
Itch reduction: By calming the lesion surface and reducing direct irritation from exudate, zinc-based products can lower perceived itch intensity.

These properties make zinc balms especially useful in acute, exudative phases of eczema and in areas prone to moisture and breakdown. For people experiencing weeping or flaking due to TSW or severe atopic dermatitis, a targeted zinc preparation can bring symptomatic relief while other long-term repair strategies — emollients and lifestyle factors — are addressed.

However, no single topical product is a universal cure. Zinc addresses the surface consequences of damaged skin more than the underlying inflammatory drivers. For chronic eczema, a layered approach typically produces the best outcomes: consistent emollient use to repair barrier function, trigger management, and anti-inflammatory therapy when needed. Zinc can be an effective adjunct, particularly when oozing or open lesions are present.

The psychological toll: isolation, stigma and "PTSD" reactions

Abeola spoke candidly about the social and psychological effects of living with severe, visible skin damage. When her skin was flaking and oozing she avoided neighbours and public exposure, and even after visible improvement she described a lingering trauma — an almost reflexive fear when a new crack or red spot appeared. She used the term "PTSD" to describe how deeply those episodes affected her confidence and daily life.

Psychological distress is common among people with visible skin disease. Anxiety and depression rates are higher in those with moderate-to-severe eczema, and social avoidance, shame and self-consciousness often accompany flares. Sleep disturbance from nighttime itch compounds mood disorders. Children pay a particular price: social development, school attendance and peer relationships can suffer when eczema is severe or persistent.

Addressing the psychological dimensions of skin disease requires more than topical therapy. Practical measures include:

Routine screening for anxiety and depression in dermatology clinics, with referrals to mental-health services when appropriate.
Connecting patients with peer support groups and patient organizations that normalise experiences and share coping strategies.
Practical problem-solving for social situations: covering lesions when practical, planning outings around treatment schedules and rehearsing brief explanations for curious acquaintances.
Mind–body strategies such as relaxation techniques, cognitive behavioural therapy (CBT) adapted for itch and sleep hygiene strategies to break the itch–scratch cycle.

Abeola’s experience also underscores the restorative effect of regained agency: developing a working topical product and helping others through her business gave her renewed confidence. For many patients, being able to help or guide others is part of recovery.

Patient education and clinical gaps: what the story reveals

Three themes stand out from Abeola’s narrative regarding how patients experience care.

Undeclared steroids in consumer products. The cream Abeola bought from a local shop, which she later discovered contained steroids, exposes a regulatory and consumer-awareness problem. When steroid-containing products are sold outside clinical channels, patients may use them without understanding the risks of prolonged unsupervised application. That increases the likelihood of local adverse effects and complicates later attempts to discontinue.
Limited information on withdrawal risks and tapering. Many patients do not receive clear instructions about the safe duration of topical steroid use, tapering strategies, or how to switch to maintenance emollients. While short courses for flares and intermittent "weekend" maintenance approaches are standard in many clinics, communication gaps leave some patients using continuous treatment for months or years without a plan for step-down.
The need for comprehensive management plans. Treating eczema effectively requires attention to triggers (allergens, irritants, heat, stress), barrier repair, anti-inflammatory therapy and psychosocial support. When treatment focuses solely on suppressing inflammation with steroids without a parallel strategy for barrier restoration and trigger control, relapse is likely.

Clinics and public-health systems can respond to these gaps with clearer patient materials, better checks on unregulated products in the marketplace, and stronger pathways for dermatology referral when patients struggle with persistent disease or suspected withdrawal. On the patient side, improved literacy about product labels, avoiding unlabelled creams, and seeking medical input before prolonged steroid use are practical, immediate steps.

Understanding topical steroid withdrawal: evidence, controversies and practical realities

Topical steroid withdrawal (TSW) is a patient‑reported phenomenon characterised by burning, redness, scaling, oozing and severe itch after cessation of topical corticosteroids, especially after prolonged use on the face or other thin-skinned areas. Researchers and clinicians debate how to define, measure and treat TSW; key points include:

No universal diagnostic criteria: TSW is primarily diagnosed clinically based on timing (worsening symptoms upon stopping TCS) and characteristic symptoms. Research groups have proposed case definitions, but consensus across dermatology remains incomplete.
Heterogeneity of presentations: Some patients improve gradually with steroid tapering and barrier repair, while others report prolonged, severe flares lasting months or years.
Mechanisms are not fully elucidated: Proposed mechanisms include steroid-induced skin atrophy and altered vasoreactivity, rebound inflammation, and dysregulation of skin immune responses. The relative contribution of undisclosed steroid exposure from unlabelled products is another complicating factor.
Management is challenging: Stopping steroids abruptly can cause severe symptoms for some, while continuing them perpetuates dependency in others. Supportive care — emollients, wound care, zinc and non-steroidal anti-inflammatory options — is central. Some clinics adopt a supervised tapering approach; others recommend specialist dermatology referral.

Clinicians increasingly recognise that whether called TSW or rebound dermatitis, some patients have severe, treatment-resistant flares related to prior steroid exposure. That recognition has to be matched by practical pathways: accessible dermatology consultation, patient education about risks and alternatives, and non-steroidal strategies for symptomatic control and barrier repair.

Abeola’s account aligns with the patient community’s experiences: cycles of reliance on steroids, worsening when treatment stopped, and a long rehabilitation phase where barrier repair and symptomatic topical agents were essential.

Balancing efficacy and safety: how to use topical steroids responsibly

Topical corticosteroids remain a cornerstone for controlling flares of eczema, when used correctly. The balance is simple in theory and intricate in practice: use enough anti-inflammatory medication to control the flare, then step down and maintain with emollients to minimise reliance on steroids. Practical principles include:

Use the right potency for the body site. Thinner skin (face, eyelids, genitals) requires lower-potency steroids; thicker areas (palms, soles) may need stronger preparations. Potency mismatch contributes to atrophy and side effects.
Follow duration recommendations. Short, supervised courses for flares are standard. If symptoms require repeated, frequent courses or continuous use, ask for a dermatology review.
Taper rather than abrupt cessation when appropriate. Some clinicians recommend a planned reduction in potency or frequency to let the skin adjust and reduce rebound risk.
Combine with regular emollients. Emollients should be the backbone of eczema care: they restore barrier function and reduce the need for anti-inflammatory treatments.
Avoid unlabelled or suspect products. Over-the-counter creams not approved or appropriately labelled may contain active drugs, including steroids, that alter outcomes and risk.
Seek specialist care for difficult cases. Referral to dermatology is sensible if disease is severe, recurrent, involves the face or genitals, or if side effects are suspected.

A patient-centred approach — shared decision-making, clear instructions, and follow-up — reduces the likelihood of steroid misuse and the distressing cycles Abeola described.

Managing flare symptoms at home: practical tactics that complement medical care

People with eczema require day-to-day strategies to manage flares and prevent escalation. The interventions below are practical, low-risk measures that complement professional care.

Emollient discipline

Apply emollient liberally and frequently; treat application as routine, not occasional. Thick creams and ointments are often more effective than lotions.
Use emollients immediately after bathing to lock in moisture.

Wet wraps and barrier protection

For severe flares or oozy skin, short-term wet wrap therapy under medical guidance can hydrate and reduce inflammation.
Zinc‑based barrier creams can protect broken skin, absorb exudate and promote healing; they are particularly useful on hands, face and perioral areas when lesions are exudative.

Antipruritic strategies

Cool compresses reduce burning and itch.
Antihistamines can help with sleep disruption from nocturnal itch, though they have limited effect on itch during the day.
Behavioural strategies — keeping nails short, using cotton gloves at night — reduce damage from scratching.

Infection vigilance

Weeping lesions are at risk of bacterial infection. Increased pain, spreading redness, pus, fever or swollen lymph nodes require medical assessment; topical or systemic antibiotics may be needed.

Lifestyle and trigger management

Identify irritants: certain soaps, detergents, fragrances and fabrics can worsen eczema.
Heat and sweating often trigger itch; clothing layers and breathable fabrics can help.
Stress management matters: psychological stress is a recognised trigger; interventions like relaxation, CBT or mindfulness support overall control.

Product selection and safety

Prefer licensed, appropriately labelled products. Be wary of inexpensive or unregulated creams that claim dramatic results.
Test new topicals on a small area before widespread use, especially if you have a history of sensitivity.

These measures do not replace medical assessment but provide immediate, practical relief while working with clinicians on a longer-term plan.

When to seek medical attention — and what to ask for

Knowing when to escalate care reduces suffering and prevents complications. Seek medical attention promptly if:

You develop fever, severe pain, rapidly spreading redness or pus.
You have persistent, large areas of weeping and crusting that do not respond to basic care.
You cannot control itch despite emollients and over-the-counter measures.
You are using topical steroids frequently or continuously without a plan to stop.
You develop thinning skin, easy bruising, purple streaks, or other signs of steroid side effects.
You notice vision changes, which could signal complications from periocular steroid use or infection.

When you consult, be proactive: bring a list of all products used (including over-the-counter creams and herbal or imported ointments). Ask about:

A clear plan for steroid use, tapering and maintenance.
Referral to dermatology for specialist management if you have severe or recurrent disease.
Wound care strategies and whether zinc, wet wraps or other topical adjuncts might help.
Psychological support or referral to patient groups, especially if the condition affects sleep, mood or ability to work or care for family.

Open communication and documentation of all topical exposures helps clinicians identify risks — including hidden steroid exposure from unlabelled products.

The marketplace problem: unlabelled creams and consumer risk

One striking detail from Abeola’s story is the unlabelled steroid-containing cream she purchased from a local shop. That single event complicates both clinical management and public safety. Key problems are:

Patients unknowingly expose themselves to potent pharmacologic agents without guidance.
Adverse effects, including atrophy and dependence, become possible when products are used long-term.
Clinicians may be misled in assessing a patient’s treatment history if installations are not reported.

Regulatory agencies and public-health authorities have a role in policing the marketplace and educating consumers. For individuals, practical steps include:

Avoiding creams from unregulated sources, particularly those sold informally without clear labelling or manufacturers’ information.
If a product causes unexpected changes or fails to list ingredients, stop use and seek medical advice.
Reporting suspect products to health authorities so they can investigate and remove harmful items.

The problem is not confined to one town or country; patient groups worldwide have documented harmful products that hide active steroids, antibiotics or other agents. Greater vigilance from regulators alongside consumer education reduces this risk.

Entrepreneurship under pressure: running a small health brand while parenting

Abeola’s experience launching and running Derma Warrior while raising three children captures the tension between solving a personal health problem and making that solution available to others. She describes getting up early to work while the children slept, leaning on a support network, and confronting the impulse to quit when pressures mount.

Small health businesses face particular burdens:

Product development must meet safety, quality and labelling requirements, which carry costs and complexity.
Customer trust depends on reliable, evidence-based claims and transparent ingredient lists.
Inventory, shipping, returns and marketing require time and systems that are hard to manage for a one-person founder.
Balancing family responsibilities adds scheduling constraints and emotional labor.

Abeola leaned on community demand — early customers who had seen her results — to create initial momentum. For parents building health-focused businesses, practical approaches include:

Prioritising tasks and setting realistic growth targets.
Automating or outsourcing logistics like order fulfillment, accounting and customer service when feasible.
Building a trusted advisory network (suppliers, regulatory consultants, clinical advisers).
Using small-scale trials and customer feedback loops to refine products before scaling.

Her statement that “we can’t have it all but we can get as close to it all as we possibly can” captures the trade-offs many juggling entrepreneurship and childcare accept. The support of family, friends and customers helped sustain Derma Warrior’s growth.

Community response: how patient networks shape understanding and care

Abeola’s customers did more than buy products; they shared stories, asking for solutions for their children and sending messages of gratitude. That conversation mirrors broader patient-driven movements in dermatology: online forums, social-media groups and local meet-ups shape how people interpret symptoms, choose products and seek providers.

Patient networks do several things:

Share lived experiences and practical hacks that clinicians may not hear about during brief consultations.
Amplify safety concerns about particular products or prescribing patterns.
Provide moral support and reduce isolation for people with disfiguring flares.
Influence market demand for products that fill gaps in clinical care (e.g., non-steroidal barrier creams, zinc-based balms).

Clinicians and regulators need to listen to these networks, engage respectfully and incorporate patient perspectives into care pathways. When patients feel heard, their adherence improves, and the risk of experimenting with unsafe alternatives declines.

What clinicians can learn from patient innovators

Abeola’s transition from patient to product-maker provides useful lessons for clinicians:

Patients identify practical unmet needs — in this case, a safe, effective topical that dries oozing lesions without magnifying reliance on steroids.
Patient solutions often emphasise simplicity, accessibility and immediate symptom relief.
Clinicians can partner with patient innovators to test tolerability, safety and formulation improvements, turning grassroots solutions into clinically vetted options.

Collaboration requires clear communication, standards for product safety and a willingness to evaluate real-world evidence. When clinicians recognise patient agency instead of dismissing home remedies, they open the door to richer, shared strategies for chronic disease management.

Practical takeaways for people living with eczema or steroid withdrawal concerns

Keep a product diary. Record every cream, ointment and supplement you use, with dates and application sites. This helps clinicians trace possible medication exposures.
Emollients are foundational. Use them frequently and liberally to maintain barrier function and reduce inflammation triggers.
Don’t stop prescribed steroids abruptly without medical guidance if you’ve been on them long-term. Ask your clinician for a tapering plan and a strategy for symptom control during transition.
Be cautious with unlabelled or imported products. If a promising remedy doesn’t list ingredients transparently, avoid it.
Consider zinc-based balms for exudative, oozy lesions as a symptomatic adjunct; they are not a replacement for long-term control strategies.
Seek specialist referral early when disease is severe, recurrent or affecting function (sleep, work, childcare).
Address mental health needs. If eczema is causing anxiety, social withdrawal or sleep disruption, ask for psychosocial support as part of your care plan.

Putting these measures into practice reduces the risk of treatment-related complications and improves quality of life.

Real-world examples beyond Abeola: patient-led relief and the need for guidance

Patient innovation in skin care is not unique to Derma Warrior. Across the globe, people living with chronic skin disease have developed topical concoctions, devised wet-wrap techniques, and created community resources that provide immediate relief. Several common themes emerge from those grassroots efforts:

Barrier-first approaches work. Many patient formulations prioritise occlusion, thick emollients and ingredients that reduce weeping.
Minimalist ingredient lists reduce irritant risk. Patients often find products with fewer potentially sensitising additives are better tolerated.
Community feedback accelerates product improvement. Real-time reports from other patients help refine formulations faster than traditional product cycles.

However, patient-led remedies require careful vetting. Safety concerns arise when home-formulated or small-batch products do not meet sterilisation, contamination control or preservation standards. Where possible, collaboration with clinicians, local laboratories or small-scale cosmetic regulators helps ensure patient solutions are safe to use broadly.

Abeola’s approach — starting small, responding to individual needs, and scaling only when demand and safety measures align — illustrates a responsible model for patient-led health entrepreneurship.

Moving forward: education, regulation and shared decision-making

Abeola’s story is a catalyst for action in three domains.

Patient education. Clear, accessible guidance on steroid use, what constitutes safe products, and how to taper is essential. Healthcare systems should develop concise materials and public campaigns aimed at communities where unregulated products are common.
Marketplace regulation. Authorities need to identify and remove mislabelled or steroid-containing products sold without prescription. Collaborative surveillance between consumers, clinicians and regulators catches harmful items faster.
Clinical pathways. Dermatology services should streamline access for patients with suspected TSW or complex eczema. Shared decision-making — where clinicians explain risks and benefits and co-create tapering and maintenance plans — reduces the chance of patients self-managing in ways that worsen outcomes.

Abeola’s emphasis on education captures the core need: treating eczema effectively requires knowledge about triggers, safe use of medicines and realistic expectations. When patients are informed, the risk of unintended harm from unlabelled products or unsupervised long-term steroid application falls.

Voices that matter: patients, clinicians and regulators in conversation

Effective management of chronic skin disease depends on all parties exchanging information respectfully. Patients bring lived experience; clinicians contribute medical knowledge; regulators protect public safety. The dialogue should be concrete:

Patients should be candid about all topicals they use.
Clinicians should explain the rationale for prescriptions, discuss duration and follow-up, and offer alternatives.
Regulators should act on reports of unsafe products and provide clear consumer-facing warnings.

Abeola’s outreach to customers and willingness to share her journey exemplify how patient stories illuminate system gaps and prompt better safeguards.

FAQ

Q: What is topical steroid withdrawal (TSW)? A: TSW refers to a pattern of symptoms — intense burning, redness, scaling, oozing and itch — that can occur after stopping prolonged or inappropriate topical corticosteroid use. The condition is variably defined and debated within dermatology, but many patients report prolonged and severe withdrawal experiences. Management typically involves supportive care, emollients, wound protection and specialist advice; tapering strategies may be recommended in some cases.

Q: Are topical steroids safe? A: When used as directed — appropriate potency for the body area, for recommended durations and with follow-up — topical corticosteroids are effective and generally safe for flare control. Risks increase with prolonged continuous use, use of high-potency steroids on thin skin, and unmonitored self-directed application. Discuss treatment duration and a step-down plan with your clinician.

Q: Can zinc balms or zinc oxide help eczema? A: Zinc-containing balms provide a protective barrier, can dry exudative lesions, reduce maceration and support wound healing. They are particularly useful for oozy, weeping eczema and can relieve itch caused by exudate. Zinc balms are adjunctive therapy, not a substitute for long-term barrier repair strategies and appropriate anti-inflammatory treatment when required.

Q: How should someone stop using topical steroids safely? A: Do not abruptly stop long-term topical steroids without medical advice. Speak to your clinician about a tapering plan — reducing potency or frequency gradually — and a parallel strategy emphasizing emollients, topical adjuncts (like zinc for oozing lesions) and psychosocial support. If symptoms worsen significantly, seek dermatology referral.

Q: What should I do about over-the-counter creams or imported ointments? A: Buy products from reputable suppliers. Avoid creams with no ingredient list or unclear labelling. If a product causes unexpected or rapid changes in your skin, stop using it and consult a clinician. Report suspicious products to local health authorities.

Q: How can people cope with the psychological effects of severe eczema? A: Seek mental-health support if anxiety, depression or social withdrawal arise. Connect with patient support groups to reduce isolation. Practical coping tools include sleep hygiene, relaxation techniques, reframing social interactions and behavioural strategies to reduce scratching. Clinicians should screen for mood disorders in long-term eczema patients.

Q: What steps can clinicians and health systems take to prevent scenarios like Abeola’s? A: Clinicians should provide clear written instructions on topical steroid use, discuss tapering and maintenance, and identify patients at risk of long-term dependency. Health systems should facilitate dermatology access for complex cases and regulators should monitor and remove mislabelled topical products from the market.

Q: Is there a role for patient-led products in skin care? A: Yes. Patient innovation often identifies unmet needs and produces practical solutions. But safety is vital: products should be transparent about ingredients, produced under hygienic conditions and, where used widely, evaluated for tolerability and contamination. Collaboration with clinicians and regulatory awareness helps ensure patient-led products remain safe and beneficial.

Q: How do I balance parenting and managing a skin-product business? A: Prioritise tasks, set realistic growth targets, leverage a support network, and automate or outsource logistics when possible. Use customer feedback for iterative product improvements and guard time for family and self-care to prevent burnout.

Q: Where can I find trusted information about eczema treatments? A: Start with general practice or dermatology clinics, professional dermatology associations, and accredited patient organisations. Ask clinicians for written plans and reputable product recommendations. Be cautious about social media claims that promise rapid cures without clinical backing.

-- End of article.